Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 12, 2005, Pages 567-569

  Eismann, U ^a   Oberschmidt, O ^a   Ehnert, M ^a   Fleeth, J ^a   Ludtke F E ^a   Struck, S ^a   Schulz, L ^a   Blatter, J ^b   Lahn, M M ^b   Ma, D ^b   Niyikiza, C ^b   Paoletti, P ^b   Hanauske, Axel R ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cancer; Dihydrofolate reductase; Gene expression; Glycinamide ribonucleotide formyl transferase; Pemetrexed; Thymidylate synthase

Indexed keywords

DIHYDROFOLATE REDUCTASE; MESSENGER RNA; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ARTICLE; CHEMOSENSITIVITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; RNA ISOLATION; SOLID TUMOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 29444433139     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43567     Document Type: Article

References (6)

1. Hanauske AR, Chen V, Paoletti P, Niyikiza C 2001 Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6: 363-373
2. Hanauske AR, Hilsenbeck SG, von Hoff DD 2004 Human tumor screening. In: Teicher BA, Andrews PA (eds): Cancer drug discovery and development: anticancer drug development guide: preclinical screenings, clinical trials, and approval. 2nd edition. Humana Press Inc, Totowa, NJ, USA, pp 63-76
3. Hazarika M, White RM, Johnson JR, Pazdur R 2004 FDA drug approval summaries: pemetrexed (Alimta). Oncologist 9: 482-488
4. Robinson DM, Kreating GM, Wagstaff AJ 2004 Pemetrexed - a review of its use in malignant pleural mesothelioma, non-small-cell lung cancer, and pancreatic cancer. Am J Cancer 3: 1175-1189
5. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV 2000 Colorectal tumors responding to 5-FU have low gene expression levels of dihydropyrimidine dehydrogenase, TS and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327
6. Zhao R, Goldman ID 2004 Alimta: a new generation antifolate. Oncologist 9: 242-244